<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666391</url>
  </required_header>
  <id_info>
    <org_study_id>UCMSC-2</org_study_id>
    <nct_id>NCT02666391</nct_id>
    <nct_alias>NCT02568956</nct_alias>
  </id_info>
  <brief_title>Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>South China Research Center for Stem Cell and Regenerative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>South China Research Center for Stem Cell and Regenerative Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the safety and exploratory efficacy of the
      umbilical cord mesenchymal stem cells for patients with ischemic heart diseases.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global left ventricular ejection fraction (LVEF)measured by echocardiography.</measure>
    <time_frame>1 week, 6 month, 12 month,18 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in infarct size and myocardial viability within the infarcted region measured by emission computed tomography (ECT).</measure>
    <time_frame>1 week, 18 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pump failure Killip classification</measure>
    <time_frame>baseline, 1 week, 1 month, 6 month, 12 month,18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association(NYHA) classification</measure>
    <time_frame>1 week, 1 month, 6 month, 12 month,18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major adverse event</measure>
    <time_frame>3 day, 1 week, 1 month, 6 month, 12 month,18 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>UCMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord mesenchymal stem cells</intervention_name>
    <arm_group_label>UCMSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Ischemic cardiomyopathy caused by acute occlusion or severe
             stenosis of anterior descending artery;

          -  LVEF (left ventricular ejection fraction): 25-45%;

          -  Age between 18 and 70, borh gender;

          -  Women of childbearing age agreed to take contraceptive measures during the whole study
             period;

          -  No psychiatric illnesses and speaking dysfunction;

          -  Informed consent.

        Exclusion Criteria:

          -  Structural heart disease, Valvular heart disease, Refractory hypertension(Unstable
             blood pressure control), LVEF&lt;24%;

          -  Serious primary diseases of the liver, kidney and hematopoietic system, Abnormal liver
             function(glutamic-pyruvic transaminase(ALT), glutamic-oxaloacetic transaminase (AST)
             is 2 times higher than the normal value), creatinine(Cr) is higher than the upper
             limit of the normal value;

          -  Patients suffered from severe arrhythmia;

          -  Patients suffered from stent thrombosis;

          -  Patients receiving immunosuppressive therapy;

          -  Patients have tumor or other lethal diseases (expectation of life&lt;6 months);

          -  Women who plan to be pregnant or are pregnant or nursing;

          -  Allergic constitution(Allergic to more than two kinds of drugs,food, or pollen);

          -  Other clinical trial participants within 3 months;

          -  Investigators judge other conditions not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuetao Pei, M.D., Ph.D</last_name>
    <phone>8610-68164807</phone>
    <email>AMMS0906@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junnian Zhou, Ph.D</last_name>
    <phone>8620-89199011</phone>
    <email>zhoujunnian@scrm.org.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Gao LR, Pei XT, Ding QA, Chen Y, Zhang NK, Chen HY, Wang ZG, Wang YF, Zhu ZM, Li TC, Liu HL, Tong ZC, Yang Y, Nan X, Guo F, Shen JL, Shen YH, Zhang JJ, Fei YX, Xu HT, Wang LH, Tian HT, Liu DQ, Yang Y. A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol. 2013 Oct 9;168(4):3191-9. doi: 10.1016/j.ijcard.2013.04.112. Epub 2013 May 4.</citation>
    <PMID>23651816</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>January 24, 2016</last_update_submitted>
  <last_update_submitted_qc>January 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

